<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03652896</url>
  </required_header>
  <id_info>
    <org_study_id>AR2018MR</org_study_id>
    <nct_id>NCT03652896</nct_id>
  </id_info>
  <brief_title>Anatomy-based Resection or Margin-based Resection for Hepatocellular Carcinoma</brief_title>
  <official_title>Anatomy-based Resection or Margin-based Resection for Hepatocellular Carcinoma: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huazhong University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huazhong University of Science and Technology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anatomical liver resection was widely accepted as first line curative therapy for
      hepatocellular carcinoma. However, number of retrospective clinical studies showed no
      priority of anatomical resection for hepatocellular, compared with non-anatomical resection.

      Surgical resection margin is a essential factor that may affect tumor prognosis. It is
      controversial whether adequate liver resection margin is associated with improved survival
      outcome in patients with hepatocellular.

      There was few prospective clinical trial to investigate whether anatomical liver resection is
      superior to non-anatomical resection or liver resection with adequate margin is superior to
      that with inadequate margin. This prospective clinical trial aims at fix these issues.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the anatomical liver resection group, liver segmentectomy or lobectomy is performed to
      insure curative resection (R0 resection). The region of liver resected is based on the
      anatomy or portal vein and hepatic vein. The liver pedicle of the tumor located lobe is
      exposed and dissected, which is principle to perform anatomical liver resection.

      In the non-anatomical liver resection group, the liver parenchyma transection is around 0-2
      cm from the tumor margin, according to tumor size and location.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>prognosis</measure>
    <time_frame>5 years</time_frame>
    <description>3 year and 5 year overall survival and disease free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>postoperative recovery</measure>
    <time_frame>30 days postoperatively</time_frame>
    <description>postoperative complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospital stay</measure>
    <time_frame>60 days postoperatively</time_frame>
    <description>hospital days after operation</description>
  </secondary_outcome>
  <other_outcome>
    <measure>surgery duration</measure>
    <time_frame>24 hours</time_frame>
    <description>time duration of liver parenchyma transection</description>
  </other_outcome>
  <other_outcome>
    <measure>volume of bleeding</measure>
    <time_frame>24 hours</time_frame>
    <description>millilitre of blood lost during operation</description>
  </other_outcome>
  <other_outcome>
    <measure>volume of transfusion</measure>
    <time_frame>24 hours</time_frame>
    <description>units of blood transfusion</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hepatocellular Carcinoma by BCLC Stage</condition>
  <arm_group>
    <arm_group_label>anatomical liver resection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>resect the tumor located liver segment or lobe</description>
  </arm_group>
  <arm_group>
    <arm_group_label>resection margin based liver resection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>non-anatomical liver resection, but insure adequate resection margin</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>anatomical liver resection</intervention_name>
    <description>Liver resection is performed to achieve R0 resection for patients with appropriate BCLC staging, indocyanine green retention rate, Child-pugh grading and adequate liver remnant.</description>
    <arm_group_label>anatomical liver resection</arm_group_label>
    <arm_group_label>resection margin based liver resection</arm_group_label>
    <other_name>non-anatomical liver resection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients diagnosed with hepatocellular carcinoma of BCLC stage A

          -  liver function Child-pugh A

          -  normal indocyanine green retention rate

          -  adequate liver remnant

        Exclusion Criteria:

          -  age less than 17 y or older than 65 y

          -  unresectable liver cancer

          -  intraoperative ablation

          -  contraindication for liver resection

          -  preoperative treatment for hepatocellular

          -  active hepatitis

          -  pregnant

          -  multi-original tumors

          -  mixed liver cancer (hepatocellular carcinoma and cholangiocellular carcinoma)

          -  tumor recurrence
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaoping Chen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Huazhong University of Science and Technology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Binhao Zhang, M.D.</last_name>
    <phone>+86 83663400</phone>
    <email>bhzhang8@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hepatic Surgery Center of Tongji Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 20, 2018</study_first_submitted>
  <study_first_submitted_qc>August 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2018</study_first_posted>
  <last_update_submitted>August 27, 2018</last_update_submitted>
  <last_update_submitted_qc>August 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huazhong University of Science and Technology</investigator_affiliation>
    <investigator_full_name>Xiaoping Chen</investigator_full_name>
    <investigator_title>Professor and Chairman</investigator_title>
  </responsible_party>
  <keyword>hepatocellular carcinoma</keyword>
  <keyword>anatomical liver resection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Extracts</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

